The University of Oxford’s Vaccine Group has launched the world’s first human clinical trial of a vaccine against Bundibugyo Ebolavirus amid the ongoing outbreak in the Democratic Republic of the Congo and Uganda.
The Phase I clinical trial will take place in Oxford and will assess the safety and immune response of the vaccine in 50 healthy adults aged between 18 and 55.